Skip to main content
Clinical Trials/RBR-2rnbw6
RBR-2rnbw6
Not yet recruiting
未知

Association assessment between oxytocin and borderline personality disorder

Faculdade de Medicina de Ribeirão Preto0 sitesOctober 20, 2019

Overview

Phase
未知
Intervention
Not specified
Conditions
Mental Disorders
Sponsor
Faculdade de Medicina de Ribeirão Preto
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 20, 2019
End Date
TBD
Last Updated
2 years ago
Study Type
Intervention
Sex
Female

Investigators

Sponsor
Faculdade de Medicina de Ribeirão Preto

Eligibility Criteria

Inclusion Criteria

  • women over 18 years of age; literate; of childbearing age; in contraceptive use for more than six months; who agree to participate by signing the Free and Informed Consent Form approved by the Ethics and Research Committee of the HCFMRP; who agree to measure levels of estrogen and progesterone to delineate the menstrual cycle; that are in the follicular phase of the cycle. For inclusion in the TPB group, women should have: a diagnosis of BPD performed using the criteria established by the DSM\-5 classification; being in outpatient treatment.
  • In the control group, only women with no history of current or previous psychiatric disorder evaluated by SCID\-5 will be admitted. In the study of continuous use, they will be admitted to women with BPD of childbearing age, over 18 years of age, without pretense of becoming pregnant within the next 6 months, who are literate and who agree to participate and sign the ICF approved by the HCFMRP Ethics and Research Committee. In addition, in this group, only women with a diagnosis of BPD will be accepted, based on the criteria established by the classification of DSM\-5 (APA, 2014\), in outpatient treatment; who agree not to modify their treatments during the study period.

Exclusion Criteria

  • Participants will be excluded from the study if they refer to clinical diseases that have a major impact on the functioning of the organism, such as degenerative diseases, neurological diseases, cancers, hematological, pulmonary, renal, hepatic and cardiovascular diseases; pregnant or lactating women.

Outcomes

Primary Outcomes

Not specified

Similar Trials